Implicaciones metabólicas y clínicas del uso de los inhibidores de la 3-hidroxi-3-metilglutaril coenzima A reductasa para el control de la hipercolesterolemia / Metabolic and clinic implications of using 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors for hypercholesterolemia control
Biosalud
; 7(1): 115-129, ene.-dec. 2008.
Article
in Spanish
| LILACS
| ID: lil-539784
Responsible library:
CO54.1
RESUMEN
La hipercolesterolemia es importante como factor de riesgo para enfermedad cardiovascular. El tratamiento con estatinas de la hipercolesterolemia, se basa en la inhibición competitiva de la 3-hidroxi-3-metilglutaril coenzima A reductasa (HMG-CoA), que cataliza un paso limitante de la biosintesis del colesterol. La presente revisión analiza la literatura cientifica relacionada con el metabolismo del colesterol y las implicaciones clínico-metabólicas del uso de estatinas para el control de colesterol.
ABSTRACT
Hypercholesterolemia is an important risk factor of cardiovascular disease. The use of statins for the treatment of hypercholesterolemia is based on the competitive inhibition of 3-hydroxy-methylglutaryl coenzyme A reductase (HMG-CoA), which catalyzes a limiting step for cholesterol biosynthesis. The present review analyses the scientific literature related to cholesterol metabolism and the metabolic and clinical implications of using stantins for hypercholesterolemia control.
Full text:
Available
Collection:
International databases
Database:
LILACS
Main subject:
Cholesterol
/
Disease
Type of study:
Risk factors
Limits:
Humans
Language:
Spanish
Journal:
Biosalud
Journal subject:
Medicine
Year:
2008
Document type:
Article
Affiliation country:
Colombia
Institution/Affiliation country:
Universidad de Caldas/CO
/
Universidad de Manizales/CO